<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04293432</url>
  </required_header>
  <id_info>
    <org_study_id>PV-TdP</org_study_id>
    <nct_id>NCT04293432</nct_id>
  </id_info>
  <brief_title>A Pharmacovigilance Study of Torsade de Pointes</brief_title>
  <official_title>A Pharmacovigilance Study of Torsade de Pointes in the Food and Drug Administration Adverse Event Reporting System Using Data Mining Algorithms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Peshawar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Peshawar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many cardiac and non-cardiac drugs are associated with TdP that may constitute a significant
      problem because of sudden cardiac death. This study aims to present a comprehensive overview
      and disproportionality analysis of TdP cases reported to the Food and Drug Administration
      Adverse Event Reporting System (FAERS) in order to identify new signals of TdP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug-induced Torsade de Pointes (TdP) is a serious but an overlooked adverse drug reaction
      because a wide range of marketed drugs associated with TdP are commonly prescribed in routine
      practice. Owing to the heightened concern of a vast number of drug-TdP associations including
      newly approved drugs, the investigators, therefore, aims to investigate drug-TdP associations
      by performing disproportionality analysis in order to identify new signals of TdP utilizing
      the individual case reports of TdP in the FAERS database.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 22, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Identification of drugs associated with TdP</measure>
    <time_frame>Cases reported to the FAERS database till 31/03/2019</time_frame>
    <description>The search includes MedDRA (v-22) Preferred Term, &quot;Torsade de Pointes (MedDRA code: 10044066) for the identification of all TdP case reports and drugs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of new signals of TdP</measure>
    <time_frame>Cases reported to the FAERS database till 31/03/2019</time_frame>
    <description>Signal detection using disproportionality analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of already known drug-TdP associations</measure>
    <time_frame>Cases reported to the FAERS database till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stratification of new signals with respect to age</measure>
    <time_frame>Cases reported to the FAERS database till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stratification of new signals with respect to gender</measure>
    <time_frame>Cases reported to the FAERS database till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trends of TdP reports in FAERS database</measure>
    <time_frame>Cases reported to the FAERS database till 31/03/2019</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the population of patients having TdP</measure>
    <time_frame>Cases reported to the FAERS database till 31/03/2019</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6670</enrollment>
  <condition>Torsades de Pointe Caused by Drug</condition>
  <arm_group>
    <arm_group_label>Group/Cohort</arm_group_label>
    <description>Torsade de Pointes induced by drugs reported to the FAERS database from inception till first quarter of 2019 (1990-2019)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drugs, Generic</intervention_name>
    <description>All drugs having â‰¥10 TdP cases reported in the FAERS database</description>
    <arm_group_label>Group/Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presented with TdP treated for any disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TdP cases reported in the FAERS database till 31/03/2019

          -  Adverse event reported was including the MedDRA term: Torsade de Pointes

        Exclusion Criteria:

          -  Drugs with less than 10 TdP reports
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Pharmacy, University of Peshawar</name>
      <address>
        <city>Peshawar</city>
        <state>Khyber Pakhtunkhwa</state>
        <zip>25000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Peshawar</investigator_affiliation>
    <investigator_full_name>Mohammad Ismail</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Pharmacy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsades de Pointes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

